Gaithersburg, Maryland – September 9, 2019: MaxCyte, the global cell-based therapies and life sciences company, announces today today that Director of Field Applications Scientists Christopher Mann, PhD, will present on “Advancing Adoptive Cellular Therapies Using Non-viral-based Engineering” at the 2nd International Conference on Lymphocyte Engineering (ICLE 2019) on Saturday 14 September at 9:50 a.m. BST.

The conference takes place September 13-15, 2019 at Novotel London West Hotel, London, United Kingdom. For more information, please visit:

About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including four announced commercial licenses. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit


For further information, please contact:


MaxCyte Inc.Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

     +1 301 944 1660


US Investor RelationsJohn Woolford



US Media Relations

Jamie Lacey-Moreira

+1 410-375-3658



+1 410 299 3310